Oleh Hornykiewicz
#30,354
Most Influential Person Now
Austrian biochemist
Oleh Hornykiewicz's AcademicInfluence.com Rankings
Oleh Hornykiewiczbiology Degrees
Biology
#2811
World Rank
#4399
Historical Rank
Biochemistry
#355
World Rank
#425
Historical Rank
Download Badge
Biology
Oleh Hornykiewicz's Degrees
- Doctorate Medicine University of Vienna
Why Is Oleh Hornykiewicz Influential?
(Suggest an Edit or Addition)According to Wikipedia, Oleh Hornykiewicz was an Austrian biochemist. Life Oleh Hornykiewicz was born in 1926 in Sykhiw , then in Poland . In 1951, he received his M.D. degree from the University of Vienna and joined the faculty of his alma mater the same year and worked there ever since. He also served for twenty years as chairman of the Institute of Biochemical Pharmacology. In 1967, he began a long association with the University of Toronto in Canada and, in 1992, he was named professor emeritus at that institution.
Oleh Hornykiewicz's Published Works
Published Works
- Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. (1973) (2688)
- Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. (1988) (1919)
- Dopamine (3-hydroxytyramine) and brain function. (1966) (1362)
- Biochemical pathophysiology of Parkinson's disease. (1987) (908)
- Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. (1960) (780)
- Biochemical aspects of Parkinson's disease (1998) (539)
- Kainic acid induced seizures: Neurochemical and histopathological changes (1983) (523)
- Receptor basis for dopaminergic supersensitivity in Parkinson's disease (1978) (468)
- [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. (1961) (431)
- The neurochemistry of Parkinson's disease: effect of L-dopa therapy. (1975) (406)
- The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. (2004) (391)
- Cortical‐basal ganglionic degeneration (1990) (390)
- Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
- Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. (1981) (356)
- Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. (2007) (330)
- Morphine catalepsy in the rat: relation to striatal dopamine metabolism. (1972) (320)
- Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). (1973) (304)
- Glutathione peroxidase activity in Parkinson's disease brain (1985) (299)
- [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. (1998) (285)
- Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease (1992) (275)
- Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. (1978) (256)
- Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease (1996) (224)
- Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey (1991) (222)
- Kainic acid-induced seizures: Dose-relationship of behavioural neurochemical and histopathological changes (1985) (210)
- Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. (2004) (208)
- Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease (2003) (206)
- Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. (1974) (202)
- Hereditary form of parkinsonism—dementia (1998) (202)
- Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. (1974) (191)
- Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. (1995) (191)
- The mechanisms of action of L-dopa in Parkinson's disease. (1974) (191)
- Brain neurotransmitter changes in Parkinson's disease (1981) (188)
- Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions (1970) (187)
- Marked disparity between age‐related changes in dopamine and other presynaptic dopaminergic markers in human striatum (2003) (187)
- Dopa‐responsive dystonia: Pathological and biochemical observations in a case (1994) (179)
- The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. (1986) (179)
- Brain catecholamines in schizophrenia — a good case for noradrenaline (1982) (178)
- Parkinson's disease: from brain homogenate to treatment. (1973) (170)
- Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. (2010) (170)
- The discovery of dopamine deficiency in the parkinsonian brain. (2006) (169)
- Globus pallidus dopamine and Parkinson motor subtypes (2008) (163)
- Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers (1985) (154)
- L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent (2002) (152)
- Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid ([3H]GABA) binding in the human brain: Alterations in Parkinson's disease (1977) (151)
- A brief history of levodopa (2010) (147)
- OCCURRENCE AND DISTRIBUTION OF AROMATIC l‐AMINO ACID (l‐DOPA) DECARBOXYLASE IN THE HUMAN BRAIN (1972) (146)
- Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. (1993) (144)
- Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. (1978) (143)
- Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. (1982) (139)
- Proposal for a noradrenaline hypothesis of schizophrenia (2004) (138)
- The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. (1998) (135)
- Chemical neuroanatomy of the basal ganglia — normal and in Parkinson's disease (2001) (134)
- Brain neurotransmitters in dystonia musculorum deformans. (1986) (134)
- The role of brain edema in epileptic brain damage induced by systemic kainic acid injection (1984) (131)
- Clinical–Pathological study of levodopa complications (2002) (126)
- Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum (2014) (125)
- L-Glutamic Acid Decarboxylase in Parkinson's Disease: Effect of L-Dopa Therapy (1973) (124)
- [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. (1963) (123)
- Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (1999) (118)
- Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders (2017) (117)
- Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa‐Induced Dyskinesias (2002) (117)
- Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia (1998) (116)
- Parkinson's disease and its chemotherapy. (1975) (111)
- Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications (2003) (110)
- Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease (2001) (110)
- Elevated γ‐aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: Correlation with striatal dopamine loss (1986) (109)
- Dopamine miracle: From brain homogenate to dopamine replacement (2002) (107)
- Brain monoamines and parkinsonism. (1975) (99)
- Noradrenaline distribution in subcortical areas of the human brain (1977) (94)
- Metabotropic glutamate receptor type 5 in levodopa-induced motor complications (2011) (93)
- Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence (1978) (93)
- Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. (2009) (92)
- Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum (1987) (91)
- Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat. (1981) (91)
- Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an Eyewitness (2008) (89)
- GTP‐cyclohydrolase I gene mutations in hereditary progressive and dopa‐responsive dystonia (1996) (88)
- The pallido-subthalamic projection in rat: Anatomical and biochemical studies (1981) (88)
- The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical study (2012) (85)
- Low levels of astroglial markers in Parkinson’s disease: relationship to α-synuclein accumulation (2015) (85)
- Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation (2000) (80)
- Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A) (1993) (79)
- The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity (1994) (76)
- Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? (1995) (75)
- Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects (1994) (74)
- Parkinsonism induced by dopaminergic antagonists. (1975) (74)
- Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. (1996) (72)
- Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. (1991) (71)
- The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease (1988) (70)
- Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. (2001) (70)
- Ageing and neurotoxins as causative factors in idiopathic parkinson's disease—a critical analysis of the neurochemical evidence (1989) (69)
- The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy. (1978) (68)
- [3H]Vesamicol binding in human brain cholinergic deficiency disorders (1990) (67)
- Neurochemistry of Parkinsonism (1972) (65)
- Brain neurotransmitter changes in human narcolepsy (1992) (64)
- A model for the quantitative study of central dopaminergic and serotoninergic activity. (1972) (62)
- Brain glutathione peroxidase in neurodegenerative disorders. (1986) (62)
- Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1990) (61)
- Thalamic noradrenaline in Parkinson's disease: Deficits suggest role in motor and non‐motor symptoms (2012) (60)
- Beneficial effects of serotonin precursors in postanoxic action myoclonus (1976) (59)
- Technetium-99m-d,1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. (1991) (59)
- Effect of mannitol treatment on brain neurotransmitter markers in kainic acid-induced epilepsy (1987) (58)
- Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. (1991) (56)
- Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. (1990) (56)
- Sensitization of Dopamine‐Stimulated Adenylyl Cyclase in the Striatum of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Rhesus Monkeys and Patients with Idiopathic Parkinson's Disease (1992) (54)
- Neurochemical Basis of Dementia in Parkinson’s Disease (1984) (53)
- Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. (1984) (52)
- Maturational and aging effects on guanine nucleotide binding protein immunoreactivity in human brain. (1991) (52)
- Down's Syndrome Individuals Begin Life with Normal Levels of Brain Cholinergic Markers (1989) (52)
- Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. (1988) (51)
- Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys (2006) (51)
- Imbalance of brain monoamines and clinical disorders. (1982) (50)
- Dopamine and extrapyramidal motor function and dysfunction. (1972) (49)
- Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice (2011) (49)
- Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline. (2006) (49)
- Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy (1995) (48)
- Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord (1991) (46)
- Neurohumoral interactions and basal ganglia function and dysfunction. (1976) (45)
- The action of dopamine on the arterial blood pressure of the guinea-pig. (1958) (44)
- Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. (1977) (43)
- Alpha 2-adrenoceptors modulate kainic acid-induced limbic seizures. (1985) (43)
- Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. (1980) (42)
- Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. (2004) (42)
- [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis]. (1962) (42)
- The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. (2001) (41)
- Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. (1973) (41)
- Occurrence and distribution of L-DOPA decarboxylase in the human brain. (1970) (40)
- The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. (2015) (39)
- Dementia, parkinsonism, and motor neuron disease: Neurochemical and neuropathological correlates (1988) (38)
- Homovanillic acid in different regions of the human brain: attempt at localizing central dopamine fibres. (1968) (37)
- α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter (2004) (36)
- A Sensitive and Reliable Assay for Dopamine (β‐Hydroxylase in Tissue (1980) (36)
- [Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man]. (1962) (35)
- Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future (1970) (35)
- Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of Parkinsonism (2013) (34)
- Brain noradrenaline and schizophrenia. (1986) (34)
- 9 – Dopamine and Its Physiological Significance in Brain Function (1972) (34)
- Opioid peptides in Huntington's disease: Alterations in prodynorphin and proenkephalin system (1986) (33)
- Chronic neuroleptic therapy: tolerance and GABA systems. (1977) (33)
- Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat (1992) (33)
- Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of Parkinsonism. (1971) (33)
- Biochemical evidence for brain neurotransmitter changes in idiopathic torsion dystonia (dystonia musculorum deformans). (1988) (32)
- Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation. (1988) (31)
- Dopamine in thelimbic regions of the human brain: normal and abnormal. (1977) (31)
- Identification of a noradrenaline‐rich subdivision of the human nucleus accumbens (2006) (29)
- Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients (2009) (28)
- Kainic acid-induced seizures: potentiation by α-methyl-p-tyrosine (1989) (27)
- [Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS]. (1966) (27)
- Serotonergic denervation partially protects rat striatum from kainic acid toxicity (1982) (26)
- Substantia nigra and pentylenetetrazol threshold in rats: Correlation with striatal dopamine metabolism (1979) (26)
- Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter (2001) (26)
- A Quarter Century of Brain Dopamine Research (1986) (25)
- The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. (1983) (25)
- Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications (2017) (25)
- The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat. (1988) (25)
- Catecholamines in Regulation of Motor Function (1975) (24)
- Limbic seizures without brain damage after injection of low doses of kainic acid into the amygdala of freely moving rats (1989) (24)
- How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago. (2001) (23)
- Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: The symptomatic versus the asymptomatic condition (1992) (23)
- Alterations in benzodiazepine and GABA receptor binding in rat brain following systemic injection of kainic acid (1983) (23)
- Benzodiazepine Receptor Binding in Cerebellar Cortex: Observations in Olivopontocerebellar Atrophy (1984) (22)
- The Pharmacology of Psychotherapeutic Drugs (1969) (21)
- Monoaminergic Systems in the Human Limbic Brain (1978) (21)
- The Neurochemical Basis of the Pharmacology of Parkinson’s Disease (1989) (20)
- Striatal Dopamine in Dopa-Responsive Dystonia: Comparison with Idiopathic Parkinson’s Disease and Other Dopamine-Dependent Disorders (1995) (20)
- Relationship between hypothalamic and median eminence catecholamines and thyroid function. (1972) (20)
- Some mechanisms of brain edema studied in a kainic acid model. (1990) (20)
- Increased GABA receptor binding in dominantly-inherited cerebellar ataxias (1983) (20)
- Brain monoamines in the rhesus monkey during long-term neuroleptic administration. (1980) (19)
- [Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism]. (1965) (19)
- The uptake of adrenaline and noradrenaline by blood platelets of the pig. (1958) (19)
- Decreased binding of the D-3 dopamine receptor-preferring ligand [C-11]-()-PHNO in drug-nave Parkinsons disease (2009) (19)
- Experimental midbrain lesions: neurochemical comparison between the animal model and Parkinson's disease. (1971) (18)
- Cholinergic markers in ALS spinal cord (1992) (18)
- Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain (2011) (18)
- Brain neurotransmitter abnormalities in neuronal intranuclear inclusion body disorder (1985) (18)
- Brain benzodiazepine receptor binding and purine concentration in Lesch-Nyhan syndrome (1985) (17)
- THE ROLE OF BRAIN DOPAMINE (3-HYDROXYTYRAMINE) IN PARKINSONISM (1964) (17)
- Brain Dopamine and Ageing (1985) (16)
- [ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM]. (1964) (16)
- Dopamine and Parkinson's disease. A personal view of the past, the present, and the future. (2001) (16)
- Parkinson's disease: low density and presynaptic location of D3 dopamine receptors (1981) (16)
- [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome]. (1961) (15)
- Molecular and biochemical aspects of hereditary progressive and dopa-responsive dystonia. (1998) (15)
- Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders. (1974) (15)
- Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease. (1994) (15)
- Reduced Striatal [3H]Inositol 1,4,5‐Trisphosphate Binding in Huntington's Disease (1991) (15)
- Reversible drug-induced parkinsonism: clinicopathologic study of two cases (1983) (14)
- Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens (2007) (14)
- Striatal ganglioside levels in the rat following kainic acid lesions: Comparison with Huntington's disease (2004) (14)
- GABA-dopamine relationship in Parkinson's disease striatum. (1987) (13)
- Dopamine in the earthworm, Lumbricus terrestris: enhancement of rhythmic contractile activity. (1972) (13)
- The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats. (1987) (12)
- [Effect of sex hormones of the p-polyphenoloxidase activity of the human blood serum]. (1954) (12)
- Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective (1992) (12)
- l-DOPA treatment in Parkinson's disease: Effect on dopamine and related substances in discrete brain regions (1971) (12)
- Cortical and subcortical projected foci in cats (1975) (11)
- [Behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors]. (1962) (11)
- Metabolism of dopamine and L-dopa in the human brain (1973) (11)
- [On the diagnostic value of homovanillic acid in the cerebrospinal fluid]. (1967) (11)
- L-DOPA (2017) (11)
- Advances in Parkinsonism : biochemistry, physiology, treatment (1976) (10)
- Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications (2017) (10)
- Importance of Topographic Neurochemistry in Studying Neurotransmitter Systems in Human Brain: Critique and New Data (1981) (10)
- Dopamine inhibits cell growth and cell cycle by blocking ribonucleotide reductase (2005) (10)
- THE MECHANISMS OF ACTION OF L-DOPA IN PARKINSON'S DISEASE (1975) (10)
- Changes in histamine in the rat striatum following local injection of kainic acid (1981) (10)
- The metabolism of brain dopamine in human parkinsonism. (1970) (9)
- [Central effect of reserpine on the circulatory reflexes of the carotid sinus]. (1966) (9)
- Brain Norepinephrine and Dopamine in Schizophrenia (1979) (9)
- The effect of beta-endorphin and met-enkephalin on striatin dopamine metabolism and catalepsy: comparison with morphine. (1977) (9)
- Historical aspects and frontiers of Parkinson's disease research. (1977) (9)
- B-HT 958--an antagonist at alpha 2-adrenoceptors and an agonist at dopamine autoreceptors in the brain. (1984) (9)
- Pharmacology and pathophysiology of dopaminergic neurons. (1971) (9)
- Neuroimaging and neuropathology. (1988) (9)
- Evidence for Neuronal Localization of Histamine‐N‐Methyltransferase in Rat Brain (1981) (9)
- THE DISTRIBUTION AND METABOLISM OF CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN HUMAN BRAIN (1964) (9)
- The pathochemical perspectives of Parkinson's disease. An attempt at a neurochemical definition. (1988) (8)
- Cortical-basal ganglionic degeneration (2011) (8)
- Cerebrospinal fluid homovanillic acid in cerebral infarction. (1978) (8)
- Neurochemical Aspects of Parkinson’s Disease and the Dementing Brain Disorders: Relation to Brain Ageing (1990) (8)
- Neurotransmitter Changes in Human Brain During Ageing (1987) (8)
- Cobalt infections into the substantia nigra of the rat: Effects on behavior and dopamine metabolism in the striatum (1978) (7)
- [The effect of chlorpromazine on catecholamine and 5-hydroxytryptamine metabolism in the rat brain]. (1960) (7)
- Brain Dopamine: A Historical Perspective (2002) (7)
- 50 years of levodopa (2015) (7)
- The proportionality between the uptake of adrenaline by blood platelets and their content of adenosine triphosphate. (1957) (7)
- Limbic Mechanisms (1978) (6)
- Kinetics of L-DOPA metabolism in the caudate nucleus of cats with ventrotegmental lesions. (1980) (6)
- Ultrastructural analysis of rat brain tissue following systemic kainate administration. (1986) (6)
- Cholinergic deficit induced by ethylcholine aziridinium (AF64A) in rat hippocampus: Effect on glutamatergic systems (1991) (6)
- A marked contrast between serotonergic and dopaminergic changes in dopa-responsive dystonia (2016) (6)
- [Demonstration of 5-hydroxytryptamine in the carcinoid of the small intestine described by Kahr]. (1956) (5)
- The kainic acid model of human temporal lobe epilepsy: The superiority of intra-amygdaloid injection versus other application routes (1990) (5)
- [Biological effects of bronchial carcinoid extracts]. (1959) (5)
- BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS (1988) (5)
- [On dopamine (hydroxytyramine) metabolism in the rat brain]. (1959) (4)
- A sensitive and reliable assay for dopamine beta-hydroxylase in tissue. (1980) (4)
- Kainic acid-induced seizures: potentiation by alpha-methyl-p-tyrosine. (1989) (4)
- Cellular effects of dopamine--beyond oxidative mechanisms. (2002) (3)
- Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid (2005) (3)
- Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
- SOME REMARKS CONCERNING THE POSSIBLE ROLE OF BRAIN MONOAMINES (DOPAMINE, NORADRENALINE, SEROTONIN) IN MENTAL DISORDERS (1975) (3)
- MOTOR ASPECTS OF BASAL GANGLIA DISORDERS: THE EXAMPLE OF PARKINSON'S DISEASE (1978) (2)
- [Experimental-pharmacological and clinical studies on a new spasmolytic "Spadon" (test name P 201-1)]. (1963) (2)
- L-DOPA-chlorpromazine antagonism on running activity in mice. (1974) (2)
- Experimental Model of Cytotoxic Brain Edema: Systemic Administration of Kainic Acid (1985) (2)
- [Polyphenoloxidase of the human blood serum]. (1953) (2)
- 39th Annual European Brain and Behaviour Society Abstracts (2007) (2)
- Dopamine, Levodopa and Parkinson's Disease (2007) (2)
- Physiologic, biochemical, and pathological backgrounds of levodopa and possibilites for the future. (1970) (2)
- Brain γ-aminobutyric acid and benzodiazepine receptor binding in dialysis encephalopathy (1985) (2)
- [Effects of physostigmine, tetraethylpyrophosphate, and neostigmine on the blood pressure and pressor reflexes of the carotid sinus in rats]. (1956) (1)
- [The incidence of polyphenoloxidases in the serum of non-pregnant and pregnant women]. (1953) (1)
- The action of methylene blue on monoamine oxidase and the catecholamines and the metabolism of 5-hydroxytryptamine in brain (1961) (1)
- BRAIN NORADRENERGIC CHANGES IN A PATIENT WITH WILSONʼS DISEASE: 58 (1990) (1)
- [The effect of methylene blue on monoamine oxidase and the catechol amine and 5-hydroxytryptamine metabolism of the brain]. (1961) (1)
- ADENYLATE CYCLASE-COUPLED DOPAMINE RECEPTORS IN PARKINSON'S DISEASE (1979) (1)
- Brain monoamines and Parkinsonism. (1975) (1)
- Interaction of manganese with striatal dopamine turnover in human alpha-synuclein transgenic mice (2010) (1)
- [The influence of diethyldithiocarbamate on cerebral catecholamine, spontaneous activity and L-DOPA hyperactivity]. (1967) (0)
- [Polyphenoloxidase activity in the maternal and fetal blood]. (1953) (0)
- [ON THE MECHANISM OF ACTION OF MONOAMINE OXIDASE INHIBITORS]. (1964) (0)
- Brain gamma-aminobutyric acid and benzodiazepine receptor binding in dialysis encephalopathy. (1985) (0)
- Neuropharmacology and analgesia The pro fi le of mephedrone on human monoamine transporters differs from 3 , 4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter (2015) (0)
- [Brain dopamine and brain disorders - and what we have learned from these studies (author's transl)]. (1980) (0)
- Dr. Kish and Associates Reply (1991) (0)
- 180 SYSTEMIC ADMINISTRATION OF KAINIC ACID: AN EXPERIMENTAL MODEL OF CYTOTOXIC BRAIN EDEMA IN EPILEPTIC SEIZURES (1984) (0)
- Failure of the Neurotrophic ACTH(4–10) Analogue (BIM 22015) to Attenuate the AF64A-Induced Cholinergic Lesion in Rat Hippocampus (1995) (0)
- [Dopamine metabolism in the rabbit caudate nucleus following partial inhibition of brain monoamine oxidase by nialamide]. (1968) (0)
- [Monoamine oxidase inhibitors and dopamine-(3-hydroxytyramine-) metabolism in the brain]. (1967) (0)
- [Control of the iproniazid effect on the catecholamines and 5-hydroxytryptamine in the rat brain by chlorpromazine]. (1961) (0)
- [Oxidation of adrenaline by myocardial tissue in rat in vitro]. (1955) (0)
- Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline? (reply) (1983) (0)
- Brain Dopamine and Other Neurotransmitters in Neuronal Intranuclear Inclusion Body Disorder (1986) (0)
- [The behavior of serum copper and p-polyphenoloxydase activity in clinical and subclinical forms of hepatolenticular diseases]. (1954) (0)
- [Influence of ergot alkaloids on the effect of 2,4-dinitrophenol in vitro]. (1956) (0)
- News items (2004) (0)
- BRAIN CHOLINEACETYLTRANSFERASE AND ACETYLCHOLINESTERASE ARE NOT REDUCED IN INFANT DOWN'S SYNDROME BRAIN (1988) (0)
- L-Dopa: A Historical Perspective (2005) (0)
- BIOCHEMICAL-PHARMACOLOGICAL BASIS FOR NEW TREATMENT STRATEGIES IN PARKINSONʼS DISEASE (1984) (0)
- [Effect of cortisone on adrenal cortex hypertrophy induced by reserpine]. (1957) (0)
- DETERMINANTS OF MATERNAL AND INFANTICIDAL BEHAVIOR IN FEMALE MOUSE F1 HYBRIDS (2007) (0)
- [The life history of brain dopamine]. (1985) (0)
- Parkinson Disease. (2016) (0)
- Chemical Structures, General Clinical Use and Daily Human Dose Range of the most Frequently Used Psychotherapeutic Drugs (1969) (0)
- Parkinson’s Disease, Neurotoxins and the Dopamine Transporter (2002) (0)
- AGING AND THE CELLULAR MECHANISMS OF BASAL GANGLIA DISEASES, ESPECIALLY PARKINSON??S DISEASE (1992) (0)
- [Acute and chronic tolerance induced by sympathoicomimetic amines]. (1968) (0)
- Response : Brain Norepinephrine and Dopamine in Schizophrenia (1979) (0)
- Characteristic neurochemical changes in the substantia nigra (SN) and striatum of symptomatic versus asymptomatic dopa-responsive dystonia (DRD) (2017) (0)
- The First Half-Century : 1910 – 1959 (2018) (0)
- Reserpine and Reserpine-like Agents (1969) (0)
- [ON THE PROBLEM OF THE DEVELOPMENT OF DOPAMINERGIC NEURONS IN THE HUMN BRAIN]. (1964) (0)
- [The effect of lysergic acid diethylamide on the hypotensive effects of dopamine and adrenalin]. (1958) (0)
This paper list is powered by the following services:
Other Resources About Oleh Hornykiewicz
What Schools Are Affiliated With Oleh Hornykiewicz?
Oleh Hornykiewicz is affiliated with the following schools: